Journals / Clinical and Experimental Health Sciences / 2020 / Cilt: 10 - Sayı: 2

Camellia Sinensis Leaves Hydroalcoholic Extract Improves the Alzheimer’s Disease-Like Alterations Induced by Type 2 Diabetes in Rats

Pages
93–103
Publication Date
2020-06-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

According to the results obtained by the MWM test, C. sinensis treatment slightly improved learning.Conclusion: C. sinensis improved short-term memory and increased the locomotor activity in rats according to the results obtained by NORT, OFT, and PA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Novel investigations have confirmed that hyperglycemia is strictly associated with the development of cognitive impairment and dementia.
📊
Key Findings & Data:In our study, Camellia sinensis (green tea), which inhibits sodium-dependent glucose transporter-1 (SGLT-1), was used in the treatment of type 2 diabetes mellitus (T2DM)-induced AD-like alterations via its antidiabetic effects.Methods: High-fat diet/streptozotocin-treated rat model was chosen to provide T2DM-induced AD-like alterations.
💡
Conclusion & Impact:According to the results obtained by the MWM test, C. sinensis treatment slightly improved learning.Conclusion: C. sinensis improved short-term memory and increased the locomotor activity in rats according to the results obtained by NORT, OFT, and PA.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Camillia sinensis · sodium-dependent glucose transporter · diabetes mellitus

Abstract

Objective: Novel investigations have confirmed that hyperglycemia is strictly associated with the development of cognitive impairment and dementia. Sodium-dependent glucose transporter (SGLT) inhibitors, which are oral antidiabetic drugs, are currently being investigated as the medication in Alzheimer's disease (AD). In our study, Camellia sinensis (green tea), which inhibits sodium-dependent glucose transporter-1 (SGLT-1), was used in the treatment of type 2 diabetes mellitus (T2DM)-induced AD-like alterations via its antidiabetic effects.Methods: High-fat diet/streptozotocin-treated rat model was chosen to provide T2DM-induced AD-like alterations. Antidiabetic effects were evaluated with the measurement of blood glucose level (BGL), oral glucose tolerance test (OGTT), and insulin tolerance test (ITT). On the other hand, novel object recognition test (NORT), open field test (OFT), passive avoidance test (PAT), and Morris’s water maze (MWM) test were performed to investigate the anti-Alzheimer's effects of C. Sinensis.Results: C. sinensis tolerated BGL for a short time but metformin, the first medication prescribed for T2DM, tolerated BGL during the test for 120 min. C. sinensis increased the number of square crosses and the frequency of grooming activity in a similar manner to metformin in OFT. C. sinensis treatment improved exploratory behavior and memory retention components in NORT. The step-through latency decreased in HFD/STZ-treated rat model but it improved with metformin and C. sinensis treatment in PAT. According to the results obtained by the MWM test, C. sinensis treatment slightly improved learning.Conclusion: C. sinensis improved short-term memory and increased the locomotor activity in rats according to the results obtained by NORT, OFT, and PA.

🔖

Cite This Article

ÇAM, M. E., TAŞKIN, T. (2020). Camellia Sinensis Leaves Hydroalcoholic Extract Improves the Alzheimer’s Disease-Like Alterations Induced by Type 2 Diabetes in Rats. Clinical and Experimental Health Sciences, Cilt: 10 - Sayı: 2, 93–103. https://ajindex.com/articles/481536

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging 2007;2:347-59. Butterfield DA. Phosphoproteomics of Alzheimer disease brain: Insights into altered brain protein regulation of critical neuronal functions and their contributions to subsequent cognitive loss. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:2031-9. Association As. 2019 Alzheimer's disease facts and figures. Alzheimer's & Dementia 2019;15:321-87.
  2. Liang D, Lu H. Salivary biological biomarkers for Alzheimer’s disease. Archives of Oral Biology 2019;105:5-12.
  3. Kocahan S, Doğan Z. Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N- methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors. Clin Psychopharmacol Neurosci 2017;15:1-8. Calderon-Garcidueñas AL, Duyckaerts C. Chapter 23 - Alzheimer disease. In: Kovacs GG, Alafuzoff I, editors. Handbook of Clinical Neurology: Elsevier; 2018. p. 325-37.
  4. Beyer L, Schnabel J, Kazmierczak P, Ewers M, Schönecker S, Prix C, Meyer-Wilmes J, Unterrainer M, Catak C, Pogarell O, Perneczky R, Albert NL, Bartenstein P, Danek A, Buerger K, Levin J, Rominger A, Brendel M. Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. NeuroImage: Clinical 2019;24:101949. Albensi BC. Chapter Two - Dysfunction of mitochondria: Implications for Alzheimer's disease. In: Fernyhough P, Calcutt NA, editors. International Review of Neurobiology: Academic Press; 2019. p. 13-27.
  5. Veljkovic E, Xia W, Phillips B, Wong ET, Ho J, Oviedo A, Hoeng J, Peitsch M. Chapter 2 - Alzheimer's Disease. In: Veljkovic E, Xia W, Phillips B, Wong ET, Ho J, Oviedo A, Hoeng J, Peitsch M, editors. Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases: Academic Press; 2018. p. 13-23.
  6. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA. Risk of dementia among white and African American relatives of patients with Alzheimer disease. Jama 2002;287:329-36.
  7. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain 2018;141:1917-33.
  8. Ding F, Yao J, Rettberg JR, Chen S, Brinton RD. Early Decline in Glucose Transport and Metabolism Precedes Shift to Ketogenic System in Female Aging and Alzheimer's Mo